September 22, 2021

Volume XI, Number 265

Advertisement

September 22, 2021

Subscribe to Latest Legal News and Analysis

September 21, 2021

Subscribe to Latest Legal News and Analysis

September 20, 2021

Subscribe to Latest Legal News and Analysis
Advertisement

Webinar Recording: Incubating and Launching New Life Science Companies

This 90-minute webinar explored the processes, considerations, and other factors behind the incubation and launch of new companies by some of today’s leading venture capital firms. Our panelists addressed these key questions and topics:

  • What are common sources of ideas for new companies and how do VC business models facilitate and measure the progress and de-risking of translational science?   

  • How do venture firms approach financing a new entity and how do they balance capital at risk and value capture with syndication and/or non-dilutive funding from partnerships?

  • What are venture firms’ views on founder equity for inventors, for initial key team members, and for their own firms in their capacity as new company founders? 

  • What are key steps to creating an ideal initial management team? 

Panelists included:

  • Nessan Bermingham, PhD, Serial entreprenuer and investor; currently President & CEO, Triplet Therapeutics, Executive Chairman, Korro Bio

  • Nathaniel Brooks Horwitz, Principal, Venture Team, RA Capital Management; board member of multiple companies

  • Deborah Palestrant, PhD, PartnerHead of 4:59, 5AM Ventures

Their full bios can be found here

 

©1994-2021 Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. All Rights Reserved.National Law Review, Volume XI, Number 70
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement

About this Author

Lewis Geffen, Member, Co-chair, Life Sciences Practice, Venture Capital & Emerging Companies Practice, Mintz Levin, Venture Capital Lawyer, IP Attorney, Patent Law
Member / Co-chair, Life Sciences Practice and Co-chair, Venture Capital & Emerging Companies Practice

Lewis is a corporate and licensing attorney focused on the life sciences, with decades of experience helping companies in the sector tackle strategic issues and complete complicated transactions. He is the go-to outside lawyer for preeminent biotechnology, pharmaceutical, medical device, and medtech companies, shepherding them through financing and licensing deals that fund drug development.

617.348.1834
Advertisement
Advertisement
Advertisement